Catalyst Pharmaceuticals, Inc.

CPRXNASDAQHealthcare● Active

$31.28

+$0.01(+0.04%)

Market Cap$3.8B

P/E Ratio—

52W High$32.56

52W Low$19.05

Avg Volume2.1M

Open$31.28

Beta0.74

Overview

Catalyst Pharmaceuticals, Inc. (CPRX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CPRX · free cash flow · updated Jun 8, 2026

Core FCF metrics

CPRX · FCF · TTM · margin & CAGR

Free cash flow was $208.6M for FY2025 (fiscal year ending 2025-12-31), down 12.8% year-over-year The FCF margin was 35.4%. Five-year CAGR stands at +35.9%.

FY2025 Free Cash Flow$208.6M▼ -12.8% YoY

Trailing 12M (TTM)$208.1Mtrailing 4 quarters sum

FCF Margin35.4%$208.6M ÷ revenue

3-Year CAGR+21.6%FY2022 → FY2025

5-Year CAGR+35.9%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

CPRX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$208.7M(0M)$208.6M▼ 12.8%35.4%

FY2024$239.8M(1M)$239.3M▲ +286.8%48.6%

FY2023$143.6M(82M)$61.9M▼ 46.7%15.5%

FY2022$116.0M(0M)$116.0M▲ +95.5%54.2%

FY2021$60.4M(1M)$59.4M▲ +31.8%42.1%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

CPRX · P/FCF · FCF yield · FCF per share

Catalyst Pharmaceuticals, Inc. (CPRX) trades at a FCF yield of 5.44% and a price-to-free-cash-flow ratio of 18.4x. FCF per share stands at $1.70, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

5.44%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$1.70

TTM FCF ÷ Shares Outstanding

Price / FCF

x18.4

Share Price ÷ FCF per Share

EV / FCF (TTM)

x14.8

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

CPRX · cash flow statement · operating / investing / financing

For FY2025, Catalyst Pharmaceuticals, Inc. generated $208.7M in operating cash flow and spent 0M in capital expenditures, yielding $208.6M in free cash flow.

Operating Activities

+$208.7M

Cash from core business operations

2025-12-31

Investing Activities

−$0.1M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$17.0M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($208.7M) − |CapEx| (0M) = FCF ($208.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

CPRX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Catalyst Pharmaceuticals, Inc.YOU

CPRX

$208.6M-12.8%35.4%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Catalyst Pharmaceuticals, Inc. (CPRX) reported free cash flow of $208.6M for FY2025 (fiscal year ending 2025-12-31), down 12.8% year-over-year. The FCF margin was 35.4%.

Based on available data, Catalyst Pharmaceuticals, Inc. has maintained positive free cash flow for at least 7 fiscal year(s). FCF peaked at $239.3M in FY2024. The 5-year CAGR stands at +35.9%.

Catalyst Pharmaceuticals, Inc.'s FCF yield is 5.44% and price-to-FCF ratio is 18.4x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

CPRX free cash flow · 8 questions

Catalyst Pharmaceuticals, Inc. free cash flow was $208.6M for FY2025, down 12.8% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $208.1M.

CPRX free cash flowCPRX FCFCPRX FCF 2025CPRX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Catalyst Pharmaceuticals, Inc. · Catalyst Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026